Definitive Contract HR001117C0067
- Not listed
- This is a $523,200.00 cost-plus-fixed-fee definitive contract awarded by the Defense Threat Reduction Agency (DTRA) to the Ministry of Defence (MOD), doing business as the Defence Science and Technology Laboratory (DSTL), located in the United Kingdom. The contract is for basic research to support DTRA and Department of Homeland Security efforts to counter chemical, biological, radiological, and nuclear threats. Past MOD contracts have included developing medical countermeasures, diagnostic...
- This is a cost-plus-fixed-fee delivery order contract awarded by the Defense Threat Reduction Agency (DTRA) to the Ministry of Defence, doing business as the Defence Science and Technology Laboratory (DSTL), a United Kingdom government entity. The contract, valued at $4,226,739.50, supports the "BASE PERIOD - AD92" requirement and has an ultimate completion date of June 26, 2021. The contract is not designated as a set-aside. The award is part of a larger Indefinite Delivery Contract...
- This is a federal contract award to the Ministry of Defence (doing business as DSTL), a government entity in the United Kingdom, by the Defense Threat Reduction Agency (DTRA). The $824,565 cost-plus-fixed-fee contract supports chemical agent system testing. The work, which is not set aside, involves research and development services focused on countering chemical, biological, radiological, and nuclear threats. This includes developing medical countermeasures, diagnostic tools, conducting...
- This federal contract award, valued at $5,379,526.00, was issued by the Defense Threat Reduction Agency (DTRA) to the Ministry of Defence (MOD), doing business as the Defence Science and Technology Laboratory (DSTL), a United Kingdom government entity. The award is for a base period and does not have a set-aside designation. DSTL has an Indefinite Delivery Vehicle (IDV) contract with the National Institute of Allergy and Infectious Diseases (NIAID) worth up to $146.3 million over seven years,...
- This is a $3,947,011.00 cost-plus-fixed-fee delivery order contract awarded by the Defense Threat Reduction Agency (DTRA) to the Ministry of Defence (MOD) of the United Kingdom, operating as the Defence Science and Technology Laboratory (DSTL). The contract is for a research and development effort focused on using virus-like particles as a novel platform for delivering protective antigens against Burkholderia bacteria. The contract does not have a set-aside designation. DSTL is a...
- The Defense Threat Reduction Agency awarded a $4,387,571.00 Cost Plus Fixed Fee contract to the Ministry of Defence, doing business as D S T L, a U.K. government entity located in Great Britain. The contract is for the development of chemical and biological decision support tools, with a completion date of July 21, 2022. The work supports U.S. defense and homeland security efforts to counter emerging biological and chemical threats, and may involve activities such as research on medical...
- This is a federal contract award to the Ministry of Defence (MOD), doing business as D S T L, located in Great Britain, United Kingdom. The contract, valued at $4,385,034.00, is a Delivery Order contract with a Cost Plus Fixed Fee pricing type, awarded by the Defense Threat Reduction Agency (DTRA) for "ANTHRAX DETECTION - BASE" efforts. The contract has no set-aside designation. Based on the vendor's past performance, the work likely involves research and development services focused...
- The Defense Threat Reduction Agency (DTRA) awarded an $8.4 million cost-plus-fixed-fee definitive contract to the United Kingdom's Ministry of Defence (doing business as the Defence Science and Technology Laboratory, or DSTL) on June 10, 2024, for the generation of a novel antibody-antibiotic conjugate platform to treat melioidosis and plague. The contract, which carries an ultimate completion date of December 9, 2029, will be performed in Great Britain. This award reflects DTRA's commitment...
- The Defense Threat Reduction Agency awarded a $6.4 million cost-plus-fixed-fee definitive contract to the Ministry of Defence (doing business as Defence Science and Technology Laboratory, or DSTL) on September 28, 2022, for research and development of non-ionic surfactant vesicles as drug delivery and targeting systems for antimicrobials. The contract, which extends through September 27, 2027, will be performed in Great Britain, United Kingdom, and emerged from DTRA's Broad Agency Announcement...
- The U.S. Defense Threat Reduction Agency awarded a $3,922,194.00 cost-plus-fixed-fee definitive contract to the Ministry of Defence, doing business as DSTL, located in the United Kingdom. The contract is for the CRYSTALCAST TOOLSET and has an ultimate completion date of August 24, 2021. The contract has no set-aside designation. Based on the agency and the nature of the work, this contract supports the Defense Threat Reduction Agency's efforts to counter chemical, biological, radiological, and...
This is a Cost Plus Fixed Fee contract valued at $1,289,074.82 awarded by the Defense Advanced Research Projects Agency (DARPA) to the Ministry of Defence (MOD) of the United Kingdom, doing business as the Defense Science and Technology Laboratory (DSTL). The contract is for the "Interfering and Co-Evolving Prevention and Therapy (INTERCEPT) PROGRAM", which involves research and development services focused on countering chemical, biological, radiological, and nuclear threats. The work includes developing medical countermeasures, diagnostic tools, conducting fundamental research, and building decision support systems. This contract has no set-aside designation. The MOD/DSTL has a history of performing similar prime federal contracts for U.S. defense and homeland security agencies to address emerging biological and chemical threats.
Name | Description | Solicitation Number | FederalAgency | Type | PostedDate |
|---|---|---|---|---|---|
INTERfering and Co-Evolving Prevention and Therapy (INTERCEPT) | DARPA-BAA-16-35 | Defense Advanced Research Projects Agency | Award Notice 1/2 | 4/28/16, 9:14 AM | |
INTERfering and Co-Evolving Prevention and Therapy | DARPA-BAA-16-35 | Defense Advanced Research Projects Agency | Award Notice 2/2 | 4/3/17, 3:50 PM |
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00005 | Supplemental Agreement for work within scope | ($157k) | 1/23/23 | |
| P00004 | Supplemental Agreement for work within scope | $0 | 10/9/18 | |
| P00003 | Other Administrative Action | $507.4k | 1/2/18 | |
| P00002 | Other Administrative Action | $0 | 10/2/17 | |
| P00001 | Other Administrative Action | $0 | 4/6/17 |